ACCENT mature data presented at AACR Annual Meeting

Amplia Therapeutics (ASX:ATX; OTCQB:INNMF) is presenting mature data from its ACCENT Phase 2a trial in metastatic pancreatic cancer at the AACR Annual Meeting as part of a mini-symposium entitled Advances in Precision Oncology being held in San Diego, USA today. 

The oral presentation, delivered by Amplia’s Director of Translational Biology, Dr Terrie-Anne Cock, provides further analysis of the promising efficacy and survival data recently reported for our best-in-class FAK inhibitor, narmafotinib, in combination with standard-of-care chemotherapy. 

Key highlights from the presentation include: 

• Narmafotinib shows a manageable toxicity profile with no added burden versus chemotherapy  

• Independent central review confirmed 5 complete responses in 64 patients (8%) versus 0.2% with chemotherapy  

• Overall response rate: 36% (42% including unconfirmed responses)  

• Disease control rate: 70% versus 50% with chemotherapy  

• Median overall survival: 11.1 months; median progression-free survival: 7.7 months—both more than two months longer than chemotherapy  

• Trend toward improved overall survival across Stable Disease, Partial Response and Complete Response patients 

• Efficacy exceeds chemotherapy across all endpoints despite intermittent dosing (12 days in each 28-day cycle)  

• Future trials will employ daily dosing, which may further improve responses given observed tolerability 

Amplia CEO and Managing Director, Dr Chris Burns, commented:  

“These extremely promising clinical responses demonstrate the potential narmafotinib has in the treatment of this terrible disease. We are now focused on building on this promising data with additional clinical studies, including a pivotal study based on the ACCENT trial, as well as combination studies with the exciting new class of drugs called kRAS inhibitors.” 

Click to read the ASX announcement.